Accelerating an Oncology Drug Launch

Leah Hoffmann

A F300 pharma company was preparing to launch a new oncology drug. But its understaffed pricing and market access group was struggling to create global access plans and strategies. Expecting accelerated regulatory approvals in the US and Europe, the company’s Director of Global Pricing turned to Business Talent Group.

Our talent was a life science specialist from McKinsey with a background in project management and executive experience at two multi-billion-dollar biotech companies. He worked with the team to generate pre-launch insights, analytics, and country-level revenue forecasts. He also coordinated with vendors and stakeholders to accelerate the timing of the launch. Finally, he helped refine launch strategies for eight key markets, handing off to regional teams for execution.


Previous Article
Market Access Innovations: Pharmaceutical Affordability
Market Access Innovations: Pharmaceutical Affordability

Affordability is a major concern in health and life science—and not just in the U.S. In 2018, total prescri...

Next Article
Behind the Buzzword: Market Access
Behind the Buzzword: Market Access

If you work in Life Sciences, market access is probably a priority. But what's the best way to make it an i...

Find the perfect market access consultant.

Start a Project